Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine solution applied daily in patients with toenail fungus. This trial will study patients with mild to moderate toenail fungus disease of the big toenail and their responses to two treatment durations, 24 or 48 weeks.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks |
|
| 2 | Placebo Comparator | Vehicle (placebo) for 48 weeks |
|
| 3 | Experimental | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks |
|
| 4 | Placebo Comparator | Vehicle (placebo) for 24 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| terbinafine | Drug | Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks | Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail. | 52 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks | Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. | 52 weeks |
| Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dr. Fred D. Youngswick | Novato | California | 94945 | United States | ||
| Dr. Larry Doehring |
Not provided
This randomized, double -blind, vehicle -controlled, multicenter, parallel group study was designed to assess the efficacy, safety and tolerability of a topical formulation of terbinafine hydrogen chloride 10% topical solution (TTS10%) applied daily in patients with toenail onychomycosis. Started 07 DEC 2006 and ending 27 JUN 2008.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Terbinafine 24 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks |
| FG001 | Vehicle 24 Weeks | Vehicle (placebo) for 24 weeks |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Vehicle (placebo) once daily for 48 weeks |
|
| terbinafine | Drug | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks |
|
|
| Placebo | Drug | Vehicle (placebo) once daily for 24 weeks |
|
Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and <= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if:
|
| 52 weeks |
| Safety and Tolerability Assessed by the Number of Participants With Adverse Events | Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section. | 52 weeks |
| Northglenn |
| Colorado |
| 80234 |
| United States |
| Dr. Robert P. Dunne | Melbourne | Florida | 32935 | United States |
| Dr. Mark Ling | Newnan | Georgia | 30263 | United States |
| Dr. Jesse Plasencia | Chicago | Illinois | 60632 | United States |
| Dr. John Mallory | Overland Park | Kansas | 66215 | United States |
| Dr. Jeffrey Conrow | Topeka | Kansas | 66606 | United States |
| Dr.Michael Kaye | Covington | Louisiana | 70433 | United States |
| Dr. Max Weisfeld | Baltimore | Maryland | 21214 | United States |
| Dr. Linda Stein-Gold | Detroit | Michigan | 48202 | United States |
| Dr. Anna Glaser | St Louis | Missouri | 63104 | United States |
| Dr. Richard Scher | New York | New York | 10032 | United States |
| Dr. Joseph Jorrizo | Winston-Salem | North Carolina | 27157 | United States |
| Dr. Anne Lucky | Cincinnati | Ohio | 45230 | United States |
| Dr. Rich Phoebe | Portland | Oregon | 97210 | United States |
| Dr. Patricia Westmorland | Simpsonville | South Carolina | 29681 | United States |
| Dr. David Horowitz | Nashville | Tennessee | 37203 | United States |
| Dr. Jay Lifshen | Irving | Texas | 75061 | United States |
| Dr. Richard Pollak | San Antonio | Texas | 78229 | United States |
| Dr. Patrick Agnew | Virginia Beach | Virginia | 23464 | United States |
| Novartis Investigative Site | Various Cities | France |
| Novartis | Investigative Site | Germany |
| Novartis Investigative Site | Various Cities | Germany |
| FG002 | Terbinafine 48 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks |
| FG003 | Vehicle 48 Weeks | Vehicle (placebo) for 48 weeks |
| Safety Population |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Terbinafine 24 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks |
| BG001 | Vehicle 24 Weeks | Vehicle (placebo) for 24 weeks |
| BG002 | Terbinafine 48 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks |
| BG003 | Vehicle 48 Weeks | Vehicle (placebo) for 48 weeks |
| BG004 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks | Complete cure is defined as negative KOH microscopy and negative culture for dermatophytes and no residual involvement of the target toenail. | Intent to treat (ITT) population, Last observation carried forward (LOCF) | Posted | Number | Percentage of participants | 52 weeks |
|
|
| |||||||||||||||||||||||||||||||||||
| Secondary | Efficacy Assessed by the Percentage of Participants With Mycological Cure at the End of Study After Treating Participants for 24 or 48 Weeks | Mycological cure is defined as negative KOH microscopy and negative culture for dermatophytes. | Intent to treat (ITT) population, Last observation carried forward (LOCF) | Posted | Number | Percentage of participants | 52 weeks |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Efficacy Assessed by the Percentage of Participants With Clinical Effectiveness at the End of Study After Treating Participants for 24 or 48 Weeks | Clinical effectiveness is defined as negative KOH microscopy and negative culture for dermatophytes and <= 10% residual involvement of the target toenail. Clinical effectiveness was a composite binary variable defined as "Yes" if:
| Intent to treat (ITT) population, Last observation carried forward (LOCF) | Posted | Number | Percentage of participants | 52 weeks |
| |||||||||||||||||||||||||||||||||||||
| Secondary | Safety and Tolerability Assessed by the Number of Participants With Adverse Events | Safety and tolerability data as assessed by the number of participants with Adverse Events (AE), Serious Adverse Events, Drug discontinuation due to an AE and death. Additional details can be found in the Adverse Event Section. | Safety Population | Posted | Jan 2011 | Number | Number of participants | 52 weeks |
|
52 weeks
Safety population consisting of all participants who had at least one dose of study drug and had at least one post-baseline safety assessment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Terbinafine 24 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 24 weeks | 8 | 131 | 37 | 131 | ||
| EG001 | Vehicle 24 Weeks | Vehicle (placebo) for 24 weeks | 3 | 129 | 38 | 129 | ||
| EG002 | Terbinafine 48 Weeks | Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) for 48 weeks | 9 | 134 | 54 | 134 | ||
| EG003 | Vehicle 48 Weeks | Vehicle (placebo) for 48 weeks | 7 | 126 | 52 | 126 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute coronary syndrome | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Angina pectoris | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Arrhythmia | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Myocardial infarction | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Tachycardia | Cardiac disorders | MedDRA | Systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Gastric ulcer | Gastrointestinal disorders | MedDRA | Systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Near drowning | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Subdural haematoma | Injury, poisoning and procedural complications | MedDRA | Systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Bladder cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Bladder neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Breast cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Cervix carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Malignant melanoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Malignant melanoma in situ | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Meningioma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Systematic Assessment |
| |
| Sciatica | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Bladder prolapse | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Dysuria | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Micturition disorder | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | MedDRA | Systematic Assessment |
| |
| Epididymitis | Reproductive system and breast disorders | MedDRA | Systematic Assessment |
| |
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Influenza | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Sinusitis | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | MedDRA | Systematic Assessment |
| |
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA | Systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA | Systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA | Systematic Assessment |
|
The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Novartis Pharmaceuticals | 862-778-8300 |
| ID | Term |
|---|---|
| D014009 | Onychomycosis |
| D005533 | Foot Dermatoses |
| ID | Term |
|---|---|
| D014005 | Tinea |
| D003881 | Dermatomycoses |
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D012874 | Skin Diseases, Infectious |
| D009260 | Nail Diseases |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D005534 | Foot Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077291 | Terbinafine |
| ID | Term |
|---|---|
| D009281 | Naphthalenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D011083 | Polycyclic Compounds |
Not provided
Not provided
| Between 18 and 65 years |
|
| >=65 years |
|
| Male |
|
| Units | Counts |
|---|
| Participants |
|
|
Vehicle (placebo) for 48 weeks |
|
|
| Units | Counts |
|---|
| Participants |
|
|